DLBCL
Feature
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
From the Journals
Study confirms prognostic impact of MYC partner gene in DLBCL
The findings suggest that clinicians should adopt diagnostic strategies to identify this high-risk cohort of patients.
Conference Coverage
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
From the Journals
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
From the Journals
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
From the Journals
Intravenous CNS chemo looks best for testicular DLBCL
Intrathecal chemotherapy did not offer a benefit, according to findings from the retrospective analysis of patients with testicular diffuse large...
Conference Coverage
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
From the Journals
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
From the Journals
Dasatinib shows promise as a control agent for CAR T cells
The tyrosine kinase inhibitor dasatinib was found to transiently inhibit CAR T-cell function in a preclinical study, suggesting applicability as...
Conference Coverage
No benefit with rituximab after first CR in DLBCL
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP...